Twenty state attorneys general filed a lawsuit on Thursday against several pharmaceutical companies, accusing them of entering into “numerous illegal conspiracies” to fix generic drug prices at consumers’ expense.
Click Here: Putters
The federal lawsuit (pdf) names generic drug-makers Heritage Pharmaceuticals, Inc., Aurobindo Pharma USA, Inc., Citron Pharma, LLC, Mayne Pharma (USA), Inc., Mylan Pharmaceuticals, Inc., and Teva Pharmaceuticals USA, Inc., and concerns two drugs: doxycycline hyclate delayed release, an antibiotic used to treat a range of conditions including respiratory tract infections, and glyburide, an oral diabetes medication.
It was filed in the U.S. District Court for the District of Connecticut and labels Heritage as the “principal architect and ringleader” that helped organize a “wide-ranging series of conspiracies” to fix prices.
“The misconduct was conceived and carried out by senior drug company executives and their subordinate marketing and sales executives.”
George Jepsen, Connecticut Attorney General
“My office has dedicated significant resources to this investigation for more than two years and has developed compelling evidence of collusion and anticompetitive conduct across many companies that manufacture and market generic drugs in the United States,” said Connecticut Attorney General George Jepsen, who is leading the coalition.
The other plaintiff states are Delaware, Florida, Hawaii, Idaho, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Minnesota, Nevada, New York, North Dakota, Ohio, Pennsylvania, Virginia, and Washington.
“While the principal architect of the conspiracies addressed in this lawsuit was Heritage Pharmaceuticals, we have evidence of widespread participation in illegal conspiracies across the generic drug industry,” Jepsen said. “Ultimately, it was consumers—and, indeed, our healthcare system as a whole—who paid for these actions through artificially high prices for generic drugs.”
A release from Jepsen’s office says “the misconduct was conceived and carried out by senior drug company executives and their subordinate marketing and sales executives,” who “coordinated their schemes through direct interaction with their competitors at industry trade shows, customer conferences, and other events, as well as through direct email, phone, and text message communications.”
For example, Reuters reports:
The news comes just one day after it was revealed that the U.S. Department of Justice has charged two former Heritage executives with conspiring to fix generic prices—”the first fruits of an ongoing and sweeping investigation into generic drug price-fixing by the Department,” according to Ars Technica.
As Bloomberg reported, guilty pleas and cooperation from the two executives “could lead to charges against executives at other drugmakers.”
Forbes predicts “[t]he antitrust lawsuit and federal investigation will likely bring further political heat to the generic drug sector.”
Indeed, the lawsuit charges: “Over the last several years, however, [the] price dynamic has changed for a large number of generic drugs. Prices for dozens of generic drugs have uncharacteristically risen—some have skyrocketed—for no apparent reason, sparking outrage from public officials, payers, and consumers across the country whose costs have doubled, tripled, or in some cases increased up to 1,000 percent or more.”